JPRN-UMIN000036465已完成未知
Evaluation of effectiveness of plasma lyso-Gb3 analogues as biomarker for diagnosing of Fabry disease - Evaluation of effectiveness of plasma lyso-Gb3 analogues as biomarker for diagnosing of Fabry disease
Department of Clinical Nephroscience, Niigata University Graduate School of Medical and Dental Sciences0 个研究点目标入组 100 人开始时间: 2019年4月11日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients have pathogenic GLA mutation and already diagnosed as Fabry disease should be excluded.
研究者
相似试验
招募中
不适用
A study of usefulness of plasma lyso-GL-3 as a biomarker in patients with Fabry diseaseFabry diseaseJPRN-UMIN000037839Osaka University Graduate School of Medicine, Division of Health Science, Child Healthcare and Genetic Science Laboratory100
已完成
不适用
Validation study for lyso-Gb3 plasma concentration in healthy adult or child Japanese volunteersFabry diseaseJPRN-UMIN000016854Meiji Pharmaceutical University100
已完成
不适用
Retrospective study of lyso-Gb3 plasma concentration in Fabry patients receiving ERT/ReplagalFabry diseaseJPRN-UMIN000017152Meiji Pharmaceutical University100
撤回
4 期
To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry DiseaseFabry DiseaseNCT04143958Sanofi
尚未招募
不适用
Biomarkers Estimation in StrokeCTRI/2018/07/015026Christian Medical College